Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Sintilimab + SOX in Stage IV Gastric Cancer
NCT05177068Phase 2Active, not recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in gastric cancer (GC), sponsored by Henan Cancer Hospital. Primary endpoint: Surgical complete resection rate (R0) at 3 years. Started May 2022; status: active, not recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05177068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177068.